Home > Boards > US Listed > Biotechs > Halozyme Therapeutics (HALO)

“Physicians are very comfortable with the IV formulation”.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
jamtomorrow2 Member Profile
 
Followed By 0
Posts 170
Boards Moderated 0
Alias Born 12/04/13
160x600 placeholder
Halozyme Announces First Clinical Dosing In argenx's Phase 1 Trial Of Efgartigimod (ARGX-113) With ENHANZE® Drug Delivery Te... PR Newswire (US) - 7/17/2019 8:00:00 AM
Halozyme Announces Janssen Submits BLA To FDA For Subcutaneous Formulation Of DARZALEX® Utilizing ENHANZE® Technology PR Newswire (US) - 7/12/2019 11:59:00 AM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 7/3/2019 4:02:19 PM
Halozyme Announces CRADA With National Institute of Allergy and Infectious Diseases For Use Of ENHANZE® Drug Delivery Techno... PR Newswire (US) - 6/25/2019 8:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/17/2019 8:20:11 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/12/2019 1:41:16 PM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 6/7/2019 5:11:39 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/4/2019 4:45:58 PM
Halozyme To Participate In Upcoming Investor Conferences PR Newswire (US) - 6/4/2019 8:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/3/2019 5:24:28 PM
Halozyme Announces argenx Has Selected Second Target Under ENHANZE® Technology Collaboration And License Agreement PR Newswire (US) - 5/22/2019 1:05:00 AM
Post-effective Amendment to an S-8 Filing (s-8 Pos) Edgar (US Regulatory) - 5/14/2019 5:11:52 PM
Post-effective Amendment to an S-8 Filing (s-8 Pos) Edgar (US Regulatory) - 5/14/2019 5:08:35 PM
Halozyme To Participate In Bank of America Merrill Lynch Health Care Conference 2019 PR Newswire (US) - 5/13/2019 8:01:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/7/2019 4:14:25 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/7/2019 4:07:11 PM
Halozyme Reports First Quarter 2019 Results PR Newswire (US) - 5/7/2019 4:01:00 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 5/6/2019 4:02:13 PM
Halozyme Names Dr. Alison A. Armour As Senior Vice President Of Research And Development PR Newswire (US) - 5/6/2019 8:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/3/2019 5:08:03 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/3/2019 4:30:05 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/3/2019 4:26:35 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/3/2019 4:23:56 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/3/2019 4:21:10 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/3/2019 4:18:26 PM
jamtomorrow2   Thursday, 05/16/19 02:17:04 AM
Re: jamtomorrow2 post# 5613
Post # of 5651 
“Physicians are very comfortable with the IV formulation”.

Of course who’s to say that those wretched US doctors and hospitals, that put their own finances ahead of patients’ comfort and convenience, won’t play the very same sorry game when HALO’s other partners eventually launch their own SQ versions of their leading IV drugs. It appears that Roche is not prepared to take on these doctors and hospitals in fear of their other drugs being ostrasized. Someone in authority should take the lead here. Bribery and corruption is a serious crime and when you get a world leading Pharma caving in to it something needs to be done. At the present time HALO’s claim of having over $1b in annual royalties by 2027 looks ridiculously optimistic.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist